Droplet IV
Private Company
Funding information not available
Overview
Droplet IV is an early-stage MedTech innovator addressing a critical inefficiency in global IV therapy: residual medication left in infusion lines, which leads to patient underdosing, wasted pharmaceuticals, and contributes to antimicrobial resistance (AMR). The company's automated flushing device is designed to integrate seamlessly into hospital workflows, directly improving care quality, nurse efficiency, and environmental sustainability. Backed by clinical immersion and multiple accelerator awards, Droplet IV is positioning itself to set a new standard in IV infusion management.
Technology Platform
Automated, standalone medical device designed as an add-on to existing IV infusion sets to flush residual medication from the line, ensuring complete drug delivery.
Opportunities
Risk Factors
Competitive Landscape
No direct competitors are named, suggesting Droplet IV may have first-mover advantage in the standalone automated flushing niche. However, it competes indirectly with the entrenched standard of care (manual flushing) and faces potential future competition from large MedTech players in the infusion space (e.g., BD, Baxter) who could add similar functionality to their pumps or sets.